Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haemorrhagic risk of DOACs in patients undergoing oral surgery
2021-006514-37Phase 4Terminated
- Sponsor
- Ospedale Generale Regionale F. Miulli
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apixaban in arrhythmia and cardiac morbidity, sponsored by Ospedale Generale Regionale F. Miulli. Started Aug 2022; status: terminated.
02
Drugs
apixaban
03
Conditions
arrhythmiacardiac morbidity
Beyond the preview
Go deeper on 2021-006514-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006514-37.